Bridgeway Capital Management’s Rani Therapeutics RANI Stock Holding History

Bridgeway Capital Management’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.1K	Hold	114,500	–	–	﹤0.01%	1156
2026 Q1	$84.1K	Hold	114,500	–	–	﹤0.01%	1141
2025 Q4	$155K	Buy	+114,500	New	+$173K	﹤0.01%	1061
2025 Q3	–	Sell	-46,500	Closed	-$23.9K	–	1266
2025 Q2	$23.9K	Hold	46,500	–	–	﹤0.01%	1157
2025 Q1	$58.6K	Sell	46,500 -10,000	-18%	-$14.8K	﹤0.01%	1111
2024 Q4	$77.4K	Sell	56,500 -15,000	-21%	-$31.5K	﹤0.01%	1137
2024 Q3	$154K	Hold	71,500	–	–	﹤0.01%	1107
2024 Q2	$272K	Buy	71,500 +20,000	+39%	+$104K	0.01%	987
2024 Q1	$160K	Hold	51,500	–	–	﹤0.01%	1141
2023 Q4	$171K	Hold	51,500	–	–	﹤0.01%	1167
2023 Q3	$112K	Buy	+51,500	New	+$197K	﹤0.01%	1206

Other funds holding RANI

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bridgeway Capital Management's RANI Position: Q2 2026 in Review

Bridgeway Capital Management held its Rani Therapeutics (RANI) position steady in Q2 2026 at 114,500 shares worth $87.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

Bridgeway Capital Management first reported a position in RANI in Q3 2023 and has held it in 11 quarters since. The position peaked at $272K in Q2 2024. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

Bridgeway Capital Management held 114,500 shares of Rani Therapeutics worth $87.1K as of Q2 2026.
Bridgeway Capital Management left its Rani Therapeutics share count unchanged in Q2 2026.
Rani Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #1156 holding.
Bridgeway Capital Management first reported a position in Rani Therapeutics in Q3 2023 and has held it in 11 quarters since.
Bridgeway Capital Management's Rani Therapeutics position peaked at $272K in Q2 2024.
68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.